
{
    "text": "Biomarkers, such as PD-L1 and the tumor mutation burden (TMB), enable better selection of patients who should benefit the most from first-line ICI use.", 
    "denotations": [
        {
            "id": "T1", 
            "obj": "PD-L1", 
            "span": {
                "begin": 20, 
                "end": 25
            }
        }
    ],
    "relations": [
        {
            "id":"R1",
            "pred":"causes",
            "subj":"T2", 
          "obj":"T1"}
    ]
}